Literature DB >> 7078027

[Adenosine deaminase activity in Hodgkin's disease (author's transl)].

G Müller, K Krug, W Krüger, V Richter, F Rassoul.   

Abstract

The activity of adenosine deaminase (ADA) (EC3.5.4.4.) was determined in the blood plasma, erythrocytes, and lymphocytes of 23 patients with Hodgkin's disease and partly also in 99 control subjects. The enzyme activities were measured using adenosine as substrate and by analysis of ammonia. No correlation was found between the ADA activities in lymphocytes, erythrocytes, and blood plasma. The lymphocytes of the patients revealed lower ADA activities (U/g protein) than the lymphocytes of control subjects. The ADA activity is not reduced in plasma or erythrocytes. The lower activities of ADA in the lymphocytes of patients may be related to the impaired cell-mediated immunity of the Hodgkin's disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7078027     DOI: 10.1007/bf01716809

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  11 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

3.  [Immunopathology in Hodgkin's disease].

Authors:  P G Scheurlen
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1972

4.  Pathophysiological aspects of Hodgkin's disease.

Authors:  D Huhn
Journal:  Klin Wochenschr       Date:  1979-05-16

5.  Prostaglandin-producing suppressor cells in Hodgkin's disease.

Authors:  J S Goodwin; R P Messner; A D Bankhurst; G T Peake; J H Saiki; R C Williams
Journal:  N Engl J Med       Date:  1977-11-03       Impact factor: 91.245

6.  Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency.

Authors:  M S Coleman; J Donofrio; J J Hutton; L Hahn; A Daoud; B Lampkin; J Dyminski
Journal:  J Biol Chem       Date:  1978-03-10       Impact factor: 5.157

7.  Decreased monocyte function in patients with Hodgkin's disease.

Authors:  L Leb; J A Merritt
Journal:  Cancer       Date:  1978-05       Impact factor: 6.860

8.  Hodgkin's disease. An immunodepleting and immunosuppressive disorder.

Authors:  J J Twomey; A H Laughter; S Farrow; C C Douglass
Journal:  J Clin Invest       Date:  1975-08       Impact factor: 14.808

9.  Cellular immunity in Hodgkin's disease.

Authors:  S H Advani; H D'Silva; B P Gothoskar; K A Dinshaw; C N Nair; R Gopalkrishna; G V Talwalkar; P B Desai
Journal:  Cancer       Date:  1979-02       Impact factor: 6.860

10.  Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency.

Authors:  A Cohen; R Hirschhorn; S D Horowitz; A Rubinstein; S H Polmar; R Hong; D W Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.